News

Futurism on MSN1h
The FDA Will Use AI to Accelerate Approving Drugs
The Food and Drug Administration just announced that it will immediately start using AI across all of its centers, after ...
OpenAI and the FDA Are Holding Talks About Using AI In Drug Evaluation
High-ranking OpenAI employees have met with the FDA multiple times in recent weeks to discuss AI and a project called cderGPT ...
FDA, OpenAI discussing use of AI for drug evaluation
The FDA is looking into how AI could help with final drug approvals and improve internal tasks like checking whether an ...
American Hospital Association4d
FDA commissioner talks of shortening drug approval process, benefits of AI
Food and Drug Administration Commissioner Marty Makary, M.D., spoke about the need to shorten the length of the drug approval ...
Trump Appointed Martin Makary Targets Faster Drug Approvals With FDA Artificial Intelligence Overhaul
FDA will implement a secure generative AI system across all centers by June 30, aiming to streamline internal reviews and ...
JD Supra9d
Conditional Approval Proposals for FDA: Current Context and Potential Ramifications
Drug approval is unequivocally the linchpin to any drug development effort and, given the role of the US market in the global ...
STAT12d
U.S. health officials inject new uncertainty into approval process for Covid boosters
Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...
Fierce Pharma2d
FDA misses another approval decision target date, this time for GSK's Nucala in COPD
In the wake of mass restructuring efforts across the Department of Health and Human Services (HHS), the FDA has missed yet another approval decision target date. | GSK had expected to secure an FDA ...
Rare Disease Industry Awaits FDA Chief’s New Drug Pathway Plan
FDA Commissioner Marty Makary’s proposal to roll out a new drug approval pathway is heightening hope for the rare disease ...
Fierce Biotech10d
UPDATE: FDA misses PDUFA date for Stealth’s ultra-rare disease candidate, delaying approval decision—again
An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been ...